



4137 S Sherwood Forest Blvd, Ste 210 · Baton Rouge, LA 70816
Phone: (225) 636-1014 · epilepsyallianceamerica.org

Media Contact:

Epilepsy Alliance America
Sarah.Korba@epilepsyallianceamerica.org

Epilepsy Alliance America Announces Stronger Together Campaign for National Epilepsy Awareness Month

EAA will recognize member and outside contributions to localized epilepsy support

Baton Rouge, LA, November 8, 2021 – [Epilepsy Alliance America \(EAA\)](http://Epilepsy Alliance America (EAA)), a nationwide network of community-based epilepsy organizations dedicated to providing direct care, education and support services to people living with epilepsy and the people who care for them, announced an initiative to recognize its member organizations and supportive third parties during November, designated as National Epilepsy Awareness Month in the United States.

This initiative, #EAAStrongerTogether, will promote local awareness and fundraising efforts of Epilepsy Alliance members, as well as support from sponsor SK Life Science, Inc. and partner Greenwich Biosciences, now part of Jazz Pharmaceuticals, throughout the month.



“Localized support is a key tenet of our mission, and it requires plenty of collaboration with our wonderful members and supportive third parties,” said Jeff Sinsebox, President of Epilepsy Alliance America. “By highlighting the ongoing contributions of these organizations, we can give thanks and amplify the positive impact of their activities for the epilepsy community during this important month.”

Epilepsy Alliance America members include Epilepsy Florida, Epilepsy Alliance Louisiana, Epilepsy Services New Jersey, Epilepsy Alliance North Carolina, Epilepsy Alliance Ohio, Epilepsy Alliance West Central New York, Epilepsy Association of Western and Central PA, Puerto Rican Epilepsy Society, Epilepsy Advocacy Network, Valley Children’s Healthcare and South Carolina Advocates for Epilepsy. Members will host the following schedule of National Epilepsy Awareness Month events in their respective communities to rally support:

- Epilepsy Florida
 - [Month Long Webinar Series](#) – November 2021
- Epilepsy Alliance Louisiana
 - [Family Fun Day at the Zoo](#) – Baton Rouge, LA
- Epilepsy Alliance Ohio
 - [Seize Hope Gala](#) – November 12, 2021
- Epilepsy Alliance of West Central New York
 - [Dinner with the Doctor: Epilepsy Awareness and Pharma Update](#) – November 17, 2021
- Epilepsy Advocacy Network
 - [Bingo and Boogie](#) – Peoria Heights, Illinois – November 6, 2021
 - [Bingo and Boogie](#) – Moline, Illinois – November 13, 2021
- [Epilepsy Association of Western Pennsylvania](#)
 - Events throughout November



4137 S Sherwood Forest Blvd, Ste 210 · Baton Rouge, LA 70816
Phone: (225) 636-1014 · epilepsyallianceamerica.org

- [Epilepsy Alliance North Carolina](#)
- Epilepsy Services of New Jersey
 - [Paint the Pony Purple](#) – November 14, 2021
- [Puerto Rican Epilepsy Society](#)
- [South Carolina Advocates for Epilepsy](#)
 - Purple with a Purpose Oyster Roast – November 7, 2021
 - Stroll for Seizure Control & 5k Family Fun Run – November 13, 2021
- Valley Children's Hospital
 - [Epilepsy Caped Crusaders Virtual Walk/Run](#) – November 1-30, 2021
 - [Art for Epilepsy \(Instructor Lead-Watercolor Painting with minimal supplies needed\)](#)
 - Wrap up Epilepsy Awareness Month – December 3, 2021

SK Life Science, Inc., a subsidiary of SK Biopharmaceuticals Co., Ltd., a global pharmaceutical company focused on developing treatments for central nervous system (CNS) disorders, supports Epilepsy Alliance America as the marquee sponsor of select fundraising walks, runs, events, galas and community outreach programs that make it possible for EAA to provide vital day-to-day support, care, education and services to people with epilepsy in local communities across the United States.

As a part of the mission to provide resources for those with epilepsy and their loved ones as they advocate for their treatment goals, SK life science also assisted Epilepsy Alliance America in developing a digital library of resources, including tools to facilitate meaningful conversations among patients, caregivers and doctors about care plans. The S.T.E.P.S. discussion guide, based on findings from a nationwide survey, is available at www.epilepsyallianceamerica.org/steps-tool.

Greenwich Biosciences, Inc., now part of Jazz Pharmaceuticals, is the U.S. leader in the field of cannabinoid prescription medicines, and its lead product, EPIDIOLEX® (cannabidiol) oral solution, is approved for the treatment of seizures associated with Lennox Gastaut syndrome (LGS), Dravet syndrome, or tuberous sclerosis complex (TSC) in patients one year of age and older. The company worked with Epilepsy Alliance America in 2020 to launch [Seizures Are Signs](#), a website for families who are navigating uncontrolled seizures. The site provides an assessment tool that creates a customized doctor discussion guide, educational information, stories from families who have found a diagnosis, resources, links to advocacy groups, and more. Greenwich Biosciences is the proud sponsor of Epilepsy Alliance America's Seizure ID program which will launch at the end of November 2021.

Follow along with Epilepsy Alliance America and its members' activities during the month of November at www.epilepsyallianceamerica.org/stronger-together-2021, and learn more about the organization and its mission at www.epilepsyallianceamerica.org.

About the Epilepsy Alliance America

Epilepsy Alliance America is a nationwide network of community-based epilepsy organizations who are dedicated to confronting the spectrum of challenges created by seizures through the promotion of independence and quality of life for people with epilepsy and their families. Epilepsy Alliance America was founded in 2018 by eight leading grassroots epilepsy organizations who have unified in their mission to provide direct support to people with epilepsy, and the people who care for them.

Members of Epilepsy Alliance America have been collectively supporting people with epilepsy for decades through support services, information, education, advocacy and public awareness. As a result, the Alliance provides real epilepsy help to approximately 1 million Americans living with epilepsy.

For more information, visit the Epilepsy Alliance America website at www.epilepsyallianceamerica.org.

About SK Biopharmaceuticals Co., Ltd. and SK Life Science, Inc.



4137 S Sherwood Forest Blvd, Ste 210 · Baton Rouge, LA 70816
Phone: (225) 636-1014 · epilepsyallianceamerica.org

SK Biopharmaceuticals and its U.S. subsidiary SK life science are global pharmaceutical companies focused on the research, development and commercialization of treatments for disorders of the central nervous system (CNS). The companies have a pipeline of eight compounds in development for the treatment of CNS disorders, including epilepsy. Additionally, SK Biopharmaceuticals is focused on early research in oncology. For more information, visit SK Biopharmaceuticals' website at www.skbp.com/eng and SK life science's website at www.SKLifeScienceInc.com.

Both SK Biopharmaceuticals and SK life science are part of SK Group, one of the largest conglomerates in Korea. SK Inc., the parent company of SK Biopharmaceuticals, continues to enhance its portfolio value by executing long-term investments with a number of competitive subsidiaries in various business areas, including pharmaceuticals and life science, energy and chemicals, information and telecommunication, and semiconductors. In addition, SK Inc. is focused on reinforcing its growth foundations through profitable and practical management based on financial stability, while raising its enterprise value by investing in new future growth businesses. For more information, please visit <http://hc.sk.co.kr/en/>.

About Greenwich Biosciences and Jazz Pharmaceuticals plc

Greenwich Biosciences is now part of Jazz Pharmaceuticals, a global biopharmaceutical company whose purpose is to innovate to transform the lives of patients and their families. We are dedicated to developing life-changing medicines for people with serious diseases—often with limited or no therapeutic options. Together we are continuing our commitment to patients and pursuing innovative and differentiated therapies that establish new or better standards of care in neuroscience and oncology. We actively explore new options for patients including novel compounds, small molecules and biologics, and through cannabinoid science and innovative delivery technologies. For more information, please visit www.jazzpharmaceuticals.com.